OTCMKTS:LYRA Lyra Therapeutics (LYRA) Stock Price, News & Analysis $0.03 -0.16 (-84.21%) As of 11/17/2026 12:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartInsider TradesNews and TrendsOwnershipSEC Filings About Lyra Therapeutics Stock (OTCMKTS:LYRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lyra Therapeutics alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.2052-Week Range$0.00▼$4.59Volume266 shsAverage Volume1,040 shsMarket Capitalization$53.10 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Lyra Therapeutics is a U.S.-based biotechnology company that has focused on developing localized treatments for chronic rhinosinusitis, a long-lasting inflammatory condition affecting the nose and sinuses. The company’s investigational candidates, LYR-210 and LYR-220, are bioabsorbable implants designed to deliver mometasone furoate, a corticosteroid, directly to nasal and sinus tissues over an extended period. The treatments were developed for administration by a health care provider, with the goal of providing sustained therapy without relying solely on daily medication. Lyra has evaluated these candidates in clinical studies. They are investigational products and are not approved treatments. The company’s work has centered on the U.S. market and on developing alternatives for people whose chronic sinus symptoms are not adequately managed with existing medical care.AI Generated. May Contain Errors. Read More Lyra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreLYRA MarketRank™: 0.142037876765 of 5 starsLyra Therapeutics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingLyra Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLyra Therapeutics has received no research coverage in the past 90 days.Read more about Lyra Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyra Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyra Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Lyra Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.28% of the float of Lyra Therapeutics has been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 1.82, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently decreased by 0.15%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLyra Therapeutics does not currently pay a dividend.Dividend GrowthLyra Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Lyra Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.25% of the stock of Lyra Therapeutics is held by insiders.Percentage Held by Institutions95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyra Therapeutics' insider trading history. Receive LYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LYRA Stock News HeadlinesLyra Therapeutics (LYRA) Set to Release Earnings on TuesdayNovember 16 at 1:10 AM | americanbankingnews.comLyra Therapeutics Inc.August 29, 2026 | marketwatch.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 18 at 1:00 AM | Porter & Company (Ad)Lyra Therapeutics Ends Major Office Sublease AgreementApril 17, 2026 | tipranks.comLyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SECApril 17, 2026 | globenewswire.comAfter layoffs, Lyra Therapeutics exits Watertown and Waltham leasesApril 14, 2026 | bizjournals.comTreating allergic fungal rhinosinusitis in childrenApril 8, 2026 | msn.comLyra Therapeutics Withdraws Nasdaq Appeal, Faces Imminent DelistingMarch 16, 2026 | tipranks.comSee More Headlines LYRA Stock Analysis - Frequently Asked Questions How have LYRA shares performed this year? Lyra Therapeutics' stock was trading at $3.08 at the beginning of the year. Since then, LYRA stock has decreased by 99.0% and is now trading at $0.03. How were Lyra Therapeutics' earnings last quarter? Lyra Therapeutics, Inc. (OTCMKTS:LYRA) announced its quarterly earnings results on Wednesday, November, 12th. The company reported ($3.38) earnings per share for the quarter, beating analysts' consensus estimates of ($5.98) by $2.60. The company earned $25 thousand during the quarter, compared to the consensus estimate of $206 thousand. When did Lyra Therapeutics' stock split? Lyra Therapeutics's stock reverse split on the morning of Wednesday, May 28th 2025.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Lyra Therapeutics? Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include Ceragon Networks (CRNT), Editas Medicine (EDIT), Palantir Technologies (PLTR), Nokia (NOK), Heron Therapeutics (HRTX), Aktis Oncology (AKTS) and Advanced Micro Devices (AMD). Company Calendar Today11/18/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:LYRA Previous SymbolNASDAQ:LYRA CIK1327273 Webwww.lyratherapeutics.com Phone617-393-4600FaxN/AEmployees27Year Founded2005Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$400 thousand Price / Sales0.13 Cash FlowN/A Price / Cash FlowN/A Book Value($6.04) per share Price / Book0.00Miscellaneous Outstanding Shares1,770,000Free Float1,717,000Market Cap$53.10 thousand OptionableNo Data Beta-0.29 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:LYRA) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.